Paper Details

  1. Home
  2. Paper Details

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.

Author: DoreRobin K, HattersleyGary, HuMing-Yi, LaneNancy E, LederBenjamin Z, SingerAndrea J, ZapalowskiCarol

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Abaloparatide is a drug used to treat osteoporosis. This study evaluated the long-term effects of abaloparatide followed by alendronate on fracture risk and bone mineral density in postmenopausal women. Results showed sustained reductions in fracture risk and increased bone density across different baseline risk subgroups.
Paper Details　
Original Abstract of the Article :
In the randomized, placebo-controlled, double-blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916366/

データ提供：米国国立医学図書館（NLM）

Abaloparatide and Alendronate: A Two-Pronged Approach to Bone Health

Osteoporosis, a condition that weakens bones and increases fracture risk, can be likened to a desert landscape where bones become brittle and fragile. This research explores the effectiveness of a combination treatment using abaloparatide, a bone-building medication, followed by alendronate, another bone-strengthening drug, in reducing fracture risk and improving bone mineral density (BMD) in postmenopausal women. The authors analyzed data from a large clinical trial, examining the long-term effects of this sequential treatment approach. This research is like a camel caravan, carefully exploring the most effective routes through the desert of osteoporosis, seeking to strengthen and protect bones.

Abaloparatide and Alendronate: A Promising Combination for Bone Health

The study reveals that the combination of abaloparatide followed by alendronate significantly reduced the risk of fractures and increased BMD in postmenopausal women. The results demonstrate that this sequential treatment approach can effectively improve bone health and reduce the risk of debilitating fractures.

Building Strong Foundations: Protecting Bone Health

This research provides valuable insights into the management of osteoporosis. By understanding the effectiveness of different treatment strategies, healthcare providers can create personalized plans to strengthen bones, reduce fracture risk, and improve the quality of life for individuals living with this condition.

Dr. Camel's Conclusion

This research highlights the potential of a sequential treatment approach using abaloparatide and alendronate to effectively manage osteoporosis. By strengthening bones and reducing fracture risk, this combination therapy can help individuals navigate the challenging desert of osteoporosis and build a stronger foundation for a healthy life.

Date :
  1. Date Completed 2020-09-10
  2. Date Revised 2020-09-10
Further Info :

Pubmed ID

31411768

DOI: Digital Object Identifier

PMC6916366

Related Literature

Article Analysis
・Effects of abaloparatide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.